Jump to main content

TAKHZYRO (lanadelumab-flyo) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

Site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

Personalized HAE
Product Support

A free program to help you every
step of the way

Niki

Here are just a few ways that OnePath can help:

A dedicated Patient Support Manager
A single point of contact who is ready to assist you with your product support needs
Financial assistance options
Co-pay assistance for those who are eligible,* as well as assistance with navigating insurance coverage
Injection training
In-home training from a specially trained nurse for you and/or a caregiver on how to self-administer TAKHZYRO
Resources and education
Connecting you and your caregiver with educational resources

If you are enrolled in OnePath, you may use the free OnePath Mobile App to connect with OnePath and track your health in a personal eDiary.

*At a minimum to be eligible, patients must have commercial insurance. Other terms and conditions apply. Contact OnePath for more information.

To learn more, contact a OnePath Patient Support Manager at 1–866–888–0660 Monday through Friday, 8:30 am to 8:00 pm ET.